Evidence map›Paper›PMID 41301922›Full record

ReviewBiomedicines2025

Dual-Action Regenerative Therapies: Regeneration and Antimicrobial Effects of Platelet- and Marrow-Derived Biologics.

Claire Yuan, Samuel P Ang, Jamal J Hasoon, Reda Tolba, Qing Zhao Ruan, Christopher M Lam, Giuliano Lo Bianco, Paul J Christo, Christopher L Robinson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Platelet-rich plasma for treatment of knee osteoarthritis: a narrative review.Frontiers in pain research (Lausanne, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Claire YuanChrist's College, Cambridge University, Cambridge CB2 3BU, UK.
Samuel P AngDepartment of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-0913-3419
Jamal J HasoonDepartment of Anesthesia, Critical Care, and Pain Medicine, McGovern Medical School, UTHealth, Houston, TX 77030, USA.
Reda TolbaPain Management Department in the Anesthesiology Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi P.O. Box 112412, United Arab Emirates.
Qing Zhao RuanWarren Alpert Medical School, Brown University, Providence, RI 02912, USA.
Christopher M LamDepartment of Anesthesiology, Pain, and Perioperative Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.ORCID 0000-0002-2848-6255
Giuliano Lo BiancoAnesthesiology and Pain Department, Fondazione Istituto G. Giglio Cefalù, 90015 Palermo, Italy.ORCID 0000-0003-2705-1548
Paul J ChristoDivision of Pain, Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0001-6488-5272
Christopher L RobinsonDivision of Pain, Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-6276-9056

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review explores the dual regenerative and antimicrobial properties of platelet- and marrow-derived biologics, including platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), autologous protein solutions, and plasma fractions. These biologics, widely used in regeneration and tissue repair, offer multiplex bioactivity through growth factors, cytokines, and cellular components that promote healing while reducing infection risk. PRP and BMAC demonstrate significant regenerative effects in musculoskeletal conditions, wound healing, and cartilage repair, with platelets and leukocytes contributing antimicrobial peptides and immune modulation for more indirect regenerative mechanisms. Preparation methods, patient factors, and lack of standardization impact clinical outcomes and efficacy. While promising for reducing reliance on chronic pain medications and improving function, these therapies face limitations including inconsistent preparation and utilization protocols, limited long-term safety data, and regulatory challenges. Here, we review the need for consensus-building, standardized procedures, and robust research to optimize clinical integration and realize the full potential of biologic regenerative therapies in pain medicine.

Indexed as

autologous protein solutionsbone marrow aspirate concentrateplatelet-rich plasmaregenerative medicine

Identifiers

PMID41301922
PMCPMC12650291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.